指南与共识慢性静脉疾病静脉血栓栓塞

静脉支架置入术后抗血栓治疗:国际德尔菲共识

Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus.
指南 / 共识 · Eur J Vasc Endovasc Surg · 2018-02-12

该国际德尔菲共识通过两轮调查(第一阶段106名专家完成,来自28个国家78个静脉支架中心;第二阶段61名应答者完成,应答率58%)形成7条共识声明,其中5条达到共识标准(≥67%应答者认同或否决)。共识推荐静脉支架置入术后6-12个月内首选抗凝治疗,前2-6周首选低分子肝素,多次深静脉血栓后推荐终身抗凝,单次急性深静脉血栓支架术后6-12个月建议停用抗凝;长期抗血小板治疗的作用未达成共识。

要点

  • 静脉支架术后6-12个月内首选抗凝治疗。
  • 术后前2-6周首选低分子肝素作为抗血栓药物。
  • 多次深静脉血栓后推荐终身抗凝;单次急性深静脉血栓支架术后6-12个月建议停用抗凝。

核心结论

  • 应答者对静脉支架置入术后抗凝治疗存在共识,但目前对抗血小板药物的作用尚无共识。

研究设计与样本

  • 国际德尔菲共识研究:第一阶段电子调查包含非血栓性髂静脉病变、急性深静脉血栓和血栓后综合征三个静脉支架置入临床场景,发放给五个学会的血管外科医生、介入放射科医生和血液科医生;第一阶段结果用于制定七条共识声明,连同第一阶段结果在第二轮(第二阶段)发放给应答者评估;共识预先定义为≥67%应答者认同或否决某条声明。
  • 第一阶段由106名专家完成,来自28个国家的78个静脉支架中心;第二阶段61名应答者完成,应答率58%。

主要发现

  • 七条声明中五条达到共识标准。
  • 压迫性髂静脉病变静脉支架术后6-12个月内首选抗凝治疗。
  • 术后前2-6周首选低分子肝素作为抗血栓药物。
  • 多次深静脉血栓后推荐终身抗凝;单次急性深静脉血栓静脉支架术后6-12个月建议停用抗凝。
  • 长期抗血小板治疗的作用未达成共识。

关键数值与推荐

  • 共识预先定义为≥67%应答者认同或否决某条声明。
  • 七条共识声明中五条达到共识标准。
  • 压迫性髂静脉病变静脉支架术后6-12个月内首选抗凝治疗。
  • 术后前2-6周首选低分子肝素。
  • 多次深静脉血栓后推荐终身抗凝;单次急性深静脉血栓静脉支架术后6-12个月建议停用抗凝。

临床怎么用

  • 压迫性髂静脉病变静脉支架术后6-12个月内首选抗凝治疗(共识声明)。
  • 静脉支架术后前2-6周首选低分子肝素作为抗血栓药物(共识声明)。
  • 多次深静脉血栓后推荐终身抗凝(共识声明)。
  • 单次急性深静脉血栓静脉支架术后6-12个月建议停用抗凝(共识声明)。
  • 长期抗血小板治疗的作用尚无共识。

局限性

  • 第二阶段应答率为58%(61名应答者完成)。
  • 长期抗血小板治疗的作用未达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: Deep venous stenting is increasingly used in the treatment of deep venous obstruction; however, there is currently no consensus regarding post-procedural antithrombotic therapy. The aim of the present study was to determine the most commonly used antithrombotic regimens and facilitate global consensus. METHODS: An electronic survey containing three clinical scenarios on venous stenting for non-thrombotic iliac vein lesions, acute deep vein thrombosis (DVT), and post-thrombotic syndrome was distributed to five societies whose members included vascular surgeons, interventional radiologists, and haematologists. The results of the initial survey (phase 1) were used to produce seven consensus statements, which were distributed to the respondents for evaluation in the second round (phase 2), along with the results of phase 1. Consensus was defined a priori as endorsement or rejection of a statement by ≥ 67% of respondents. RESULTS: Phase 1 was completed by 106 experts, who practiced in 78 venous stenting centres in 28 countries. Sixty-one respondents (58% response rate) completed phase 2. Five of seven statements met the consensus criteria. Anticoagulation was the preferred treatment during the first 6-12 months following venous stenting for a compressive iliac vein lesion. Low molecular weight heparin was the antithrombotic agent of choice during the first 2-6 weeks. Lifelong anticoagulation was recommended after multiple DVTs. Discontinuation of anticoagulation after 6-12 months was advised following venous stenting for a single acute DVT. No agreement was reached regarding the role of long-term antiplatelet therapy. CONCLUSIONS: Consensus existed amongst respondents regarding anticoagulant therapy following venous stenting. At present, there is no consensus regarding the role of antiplatelet agents in this context.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Milinis K, Thapar A, Shalhoub J, et al. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg. 2018. PMID: 29449145. doi:10.1016/j.ejvs.2018.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。